Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same

US9493845B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9493845-B2
Application numberUS-201313873543-A
CountryUS
Kind codeB2
Filing dateApr 30, 2013
Priority dateJan 21, 2003
Publication dateNov 15, 2016
Grant dateNov 15, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to methods for identifying compounds that modulate untranslated region-dependent expression of a target gene. The invention particularly relates to using untranslated regions of a target gene or fragments thereof linked to a reporter gene to identify compounds that modulate untranslated region-dependent expression of a target gene. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for screening for a compound that modulates K-ras mRNA translation that is regulated by the untranslated regions (UTRs) of K-ras mRNA, said method comprising: (a) contacting a compound with a first cell engineered to express a first reporter protein translated from a first mRNA transcript comprising a first reporter gene coding sequence operably linked to a first 5′ UTR and a first 3′ UTR of K-ras mRNA, wherein the first 5′ UTR is upstream of the first reporter gene coding sequence and the first 3′ UTR is downstream of the first reporter gene coding sequence and, wherein the first reporter gene coding sequence is not the coding sequence of K-ras mRNA, wherein the 5′ UTR of K-ras mRNA is encoded by the nucleotide sequence of SEQ ID NO: 59 and the 3′ UTR of K-ras mRNA is encoded by the nucleotide sequence of SEQ ID NO: 60 and wherein the expression of the first mRNA transcript is driven by transcriptional elements from a first expression vector; (b) contacting the compound with a second cell engineered to express a second reporter protein translated from a second mRNA transcript comprising the first reporter gene coding sequence operably linked to a second 5′ UTR and a second 3′ UTR of a mRNA, wherein the second 5′ UTR is upstream of the first reporter gene coding sequence and the second 3′ UTR is downstream of the first reporter gene coding sequence, wherein the second 5′ UTR and the second 3′ UTR are each from a mRNA different than the 5′ UTR and the 3′ UTR of K-ras mRNA; and wherein the expression of the second mRNA transcript is driven by the same transcriptional elements as the first expression vector; (c) contacting the compound with a third cell engineered to express a third reporter protein translated from a third mRNA transcript comprising the first reporter gene coding sequence operably linked to the first 5′ UTR and the first 3′ UTR of the K-ras mRNA, wherein the first 5′ UTR is upstream of the first reporter gene coding sequence and the first 3′ UTR is downstream of the first reporter gene coding sequence, and wherein the expression of the third mRNA transcript is driven from a second expression vector comprising different transcriptional elements than the first expression vector; and (d) detecting the amount or activity of the first, second, and third reporter proteins, wherein (i) an alteration in the amount or activity of the first reporter protein in the presence of the compound relative to the amount or activity of the first reporter protein in the absence of the compound or the presence of a negative control, (ii) no alteration in or not substantially altered amount or activity of the second reporter protein in the presence of the compound relative to the amount or activity of the second reporter protein in the absence of the compound or the presence of the negative control, and (iii) an alteration in the amount or activity of the third reporter protein in the presence of the compound relative to the amount or activity of the third reporter protein in the absence of the compound or the presence of a negative control indicates that the compound modulates K-ras mRNA translation that is regulated by the UTRs of K-ras mRNA. 2. A method for screening for a compound that modulates K-ras mRNA translation that is regulated by the untranslated regions (UTRs) of K-ras mRNA, said method comprising: (a) contacting a compound with a first cell engineered to express a first reporter protein translated from a first mRNA transcript comprising a first reporter gene coding sequence operably linked to a first 5′ UTR and a first 3′ UTR of K-ras mRNA, wherein the first 5′ UTR is upstream of the first reporter gene coding sequence and the first 3′ UTR is downstream of the first reporter gene coding sequence, and wherein the first reporter gene coding sequence is not the coding sequence of K-ras mRNA, wherein the 5′ UTR of K-ras mRNA is encoded by the nucleotide sequence of SEQ ID NO: 59 and the 3′ UTR of K-ras mRNA is encoded by the nucleotide sequence of SEQ ID NO: 60 and wherein the expression of the first mRNA transcript is driven by transcriptional elements from a first expression vector; (b) contacting the compound with cells in a plurality of wells, wherein each well is isolated from another well and the cells in each well are engineered to express a reporter protein translated from a mRNA transcript comprising the first reporter gene coding sequence operably linked to a second 5′ UTR and a second 3′ UTR of a mRNA, wherein the second 5′ UTR is upstream of the first reporter gene coding sequence and the second 3′ UTR is downstream of the first reporter gene coding sequence, and wherein the second 5′ UTR and the second 3′ UTR are each from a mRNA different than the 5′ UTR and the 3′ UTR of K-ras mRNA; and wherein the expression of the mRNA transcript is driven by the same transcriptional elements as the first expression vector; (c) contacting the compound with a second cell engineered to express a second reporter protein translated from a second mRNA transcript comprising the first reporter gene coding sequence operably linked to the first 5′ UTR and the first 3′ UTR of the K-ras mRNA, wherein the first 5′ UTR is upstream of the first reporter gene coding sequence and the first 3′ UTR is downstream of the first reporter gene coding sequence, wherein the expression of the second mRNA transcript is driven from a second expression vector comprising different transcriptional elements than the first expression vector; and (d) detecting the amount or activity of the first and second reporter proteins and each reporter protein in each well, wherein a compound that modulates K-ras mRNA translation that is regulated by the UTRs of K-ras mRNA is identified if (i) the amount or activity of the first reporter protein in the presence of the compound is altered relative to the amount or activity of the first reporter protein in the absence of the compound or the presence of a negative control, (ii) the amount or activity of each reporter protein in each well in the presence of the compound is not altered or not substantially altered relative to the amount or activity of each reporter protein in each well in the absence of the compound or the presence of a negative control, and (iii) the amount or activity of the second reporter protein is altered relative to the amount or activity of the second reporter protein in the absence of the compound or the presence of a negative control. 3. A method for screening for a compound that modulates K-ras mRNA translation that is regulated by the untranslated regions (UTRs) of K-ras mRNA, said method comprising: (a) contacting a compound with a first composition comprising a first cell-free translation mixture and a first mRNA transcript comprising a first reporter gene coding sequence operably linked to a first 5′ UTR and a first 3′ UTR of K-ras mRNA, wherein the first 5′ UTR is upstream of the first reporter gene coding sequence and the first 3′ UTR is downstream of the first reporter gene coding sequence, wherein the first reporter gene coding sequence is not the coding sequence of K-ras mRNA, wherein the 5′ UTR of K-ras mRNA is encoded by the nucleotide sequence of SEQ ID NO: 59 and the 3′ UTR of K-ras mRNA is encoded by the nucleotide sequence of SEQ ID NO: 60 and wherein the expression of the first mRNA transcript is driven by transcriptional elements from a first expression vector; (b) contacting the compound with a second composition comprising a second cell-free translation mixture and a second mRNA transcript comprising the first reporter gene coding sequence operably linked to a second 5′ UTR and a second 3′ UTR of a mRNA, wherein the second 5′ UTR is upstream of the first reporter gene coding sequence and the second 3′ UTR is downstream of the first reporter gene coding sequence, wherein the second 5′ UTR and th

Assignees

Inventors

Classifications

  • Cytokines; Lymphokines; Interferons · CPC title

  • on expression patterns · CPC title

  • for testing antineoplastic activity · CPC title

  • Angiogenesic factors; Angiogenin · CPC title

  • Screening for pharmacological compounds · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9493845B2 cover?
The present invention relates to methods for identifying compounds that modulate untranslated region-dependent expression of a target gene. The invention particularly relates to using untranslated regions of a target gene or fragments thereof linked to a reporter gene to identify compounds that modulate untranslated region-dependent expression of a target gene. The methods of the present invent…
Who is the assignee on this patent?
Ptc Therapeutics Inc
What technology area does this patent fall under?
Primary CPC classification C12Q1/6897. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).